GAMMA Investing’s Achilles Therapeutics ACHL Stock Holding History

GAMMA Investing’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.19K	Hold	806	–	–	﹤0.01%	3839
2026 Q1	$1.19K	Hold	806	–	–	﹤0.01%	3799
2025 Q4	$1.19K	Hold	806	–	–	﹤0.01%	3738
2025 Q3	$1.19K	Hold	806	–	–	﹤0.01%	3579
2025 Q2	$1.19K	Hold	806	–	–	﹤0.01%	3505
2025 Q1	$1.19K	Buy	+806	New	+$1.05K	﹤0.01%	3527

Other funds holding ACHL

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

GAMMA Investing's ACHL Position: Q2 2026 in Review

GAMMA Investing held its Achilles Therapeutics (ACHL) position steady in Q2 2026 at 806 shares worth $1.19K. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

GAMMA Investing first reported a position in ACHL in Q1 2025 and has held it in 6 quarters since. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2026.

GAMMA Investing held 806 shares of Achilles Therapeutics worth $1.19K as of Q2 2026.
GAMMA Investing left its Achilles Therapeutics share count unchanged in Q2 2026.
Achilles Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3839 holding.
GAMMA Investing first reported a position in Achilles Therapeutics in Q1 2025 and has held it in 6 quarters since.
2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.